PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

Alzamend Neuro, Inc. (ALZN)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINUS02262M3088
CUSIP02262M308
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$6.38B
EPS$0.73
PE Ratio18.21
PEG Ratio1.17
Revenue (TTM)$1.09B
Gross Profit (TTM)$810.40M
EBITDA (TTM)$811.96M
Year Range$9.01 - $13.46
Target Price$13.07
Short %4.11%
Short Ratio5.52

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Alzamend Neuro, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-99.45%
8.20%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ALZN

Alzamend Neuro, Inc.

Popular comparisons: ALZN vs. SAVA

Return

Alzamend Neuro, Inc. had a return of -86.78% year-to-date (YTD) and -93.56% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-86.78%19.67%
1 month-27.74%8.42%
6 months-89.77%7.29%
1 year-93.56%12.71%
5 years (annualized)N/A10.75%
10 years (annualized)N/A9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202332.72%-29.75%-11.18%-42.16%-9.54%-50.75%-30.90%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Alzamend Neuro, Inc. (ALZN) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ALZN
Alzamend Neuro, Inc.
-1.01
^GSPC
S&P 500
0.91

Sharpe Ratio

The current Alzamend Neuro, Inc. Sharpe ratio is -1.01. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-1.01
0.91
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

Dividend History


Alzamend Neuro, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-99.45%
-4.21%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alzamend Neuro, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alzamend Neuro, Inc. was 99.51%, occurring on Nov 27, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.51%Jun 16, 2021617Nov 27, 2023

Volatility Chart

The current Alzamend Neuro, Inc. volatility is 45.89%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
45.89%
2.79%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)